Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial
1 other identifier
interventional
20
1 country
1
Brief Summary
The goal of the proposed project is to improve the primary care treatment of veterans with alcohol dependence. Alcohol dependence is a common behavioral health problem among veterans treated in VA primary care clinics. However, assessment and treatment of alcohol dependence in primary care remains problematic. Assessment of veterans with positive alcohol use screens may not always be completed and referrals to specialty care may not always be made. Moreover, the use of medications for alcohol dependence among veterans is rare, despite VA treatment guidelines that recommend such use. Finally, when medications are prescribed, patients may have difficulties with adherence. The primary aim of this study is to assess the feasibility of long-acting injectable naltrexone provided through primary care (LAN/PC) versus long-acting injectable naltrexone in the specialized chemical dependence clinic (LAN/CDC). The secondary aim is to obtain preliminary assessments of the relative effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Oct 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2006
CompletedFirst Submitted
Initial submission to the registry
April 13, 2007
CompletedFirst Posted
Study publicly available on registry
April 18, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2007
CompletedOctober 24, 2011
October 1, 2011
1.2 years
April 13, 2007
October 21, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Primary Outcomes: Feasibility of an injectable naltrexone study in the primary care setting.
Secondary Outcomes (1)
Secondary Outcome: Effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic.
Interventions
Eligibility Criteria
You may qualify if:
- Participants must be males or non-pregnant females between the ages of 18 and 69 who are receiving their primary medical care at the Syracuse VAMC.
- Participants must meet DSM-IV diagnostic criteria for current alcohol dependence.
- Participants must report drinking within the thirty days prior to study entry.
- Participants must receive approval from their primary care provider for study participation.
- Participants must be willing to consider accepting at least one of the two treatment conditions.
You may not qualify if:
- Participants with a current DSM-IV diagnosis of current opioid abuse or dependence, or in opioid withdrawal
- AST level is greater than 3 times the upper limit of the normal range
- Participants with a medical condition requiring opioid medication or a severe allergy to naltrexone
- Participants who received outpatient treatment at the Syracuse VA Chemical Dependence Clinic in the past 90 days
- Any unstable medical or psychiatric conditions in the judgment of the principal investigator or the participants primary care provider
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Syracuse VAMC
Syracuse, New York, 13210, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Steven L Batki, M.D.
Executive Director VA Center for Integrated Healthcare, Syracuse VA Medical Center
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 13, 2007
First Posted
April 18, 2007
Study Start
October 1, 2006
Primary Completion
December 1, 2007
Study Completion
December 1, 2007
Last Updated
October 24, 2011
Record last verified: 2011-10